Literature DB >> 10844007

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

R J Ferrante1, O A Andreassen, B G Jenkins, A Dedeoglu, S Kuemmerle, J K Kubilus, R Kaddurah-Daouk, S M Hersch, M F Beal.   

Abstract

Huntington's disease (HD) is a progressive neurodegenerative illness for which there is no effective therapy. We examined whether creatine, which may exert neuroprotective effects by increasing phosphocreatine levels or by stabilizing the mitochondrial permeability transition, has beneficial effects in a transgenic mouse model of HD (line 6/2). Dietary creatine supplementation significantly improved survival, slowed the development of brain atrophy, and delayed atrophy of striatal neurons and the formation of huntingtin-positive aggregates in R6/2 mice. Body weight and motor performance on the rotarod test were significantly improved in creatine-supplemented R6/2 mice, whereas the onset of diabetes was markedly delayed. Nuclear magnetic resonance spectroscopy showed that creatine supplementation significantly increased brain creatine concentrations and delayed decreases in N-acetylaspartate concentrations. These results support a role of metabolic dysfunction in a transgenic mouse model of HD and suggest a novel therapeutic strategy to slow the pathological process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10844007      PMCID: PMC6772461     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  Creatine and cyclocreatine attenuate MPTP neurotoxicity.

Authors:  R T Matthews; R J Ferrante; P Klivenyi; L Yang; A M Klein; G Mueller; R Kaddurah-Daouk; M F Beal
Journal:  Exp Neurol       Date:  1999-05       Impact factor: 5.330

2.  Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse.

Authors:  V C Wheeler; W Auerbach; J K White; J Srinidhi; A Auerbach; A Ryan; M P Duyao; V Vrbanac; M Weaver; J F Gusella; A L Joyner; M E MacDonald
Journal:  Hum Mol Genet       Date:  1999-01       Impact factor: 6.150

3.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization.

Authors:  A Sawa; G W Wiegand; J Cooper; R L Margolis; A H Sharp; J F Lawler; J T Greenamyre; S H Snyder; C A Ross
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

Review 4.  Spatial localization in NMR spectroscopy in vivo.

Authors:  P A Bottomley
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

5.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.

Authors:  V O Ona; M Li; J P Vonsattel; L J Andrews; S Q Khan; W M Chung; A S Frey; A S Menon; X J Li; P E Stieg; J Yuan; J B Penney; A B Young; J H Cha; R M Friedlander
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

6.  Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.

Authors:  R T Matthews; L Yang; B G Jenkins; R J Ferrante; B R Rosen; R Kaddurah-Daouk; M F Beal
Journal:  J Neurosci       Date:  1998-01-01       Impact factor: 6.167

7.  Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism.

Authors:  S Stöckler; F Hanefeld; J Frahm
Journal:  Lancet       Date:  1996-09-21       Impact factor: 79.321

8.  Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease.

Authors:  M B Bogdanov; R J Ferrante; S Kuemmerle; P Klivenyi; M F Beal
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

Review 9.  Creatine in humans with special reference to creatine supplementation.

Authors:  P D Balsom; K Söderlund; B Ekblom
Journal:  Sports Med       Date:  1994-10       Impact factor: 11.136

Review 10.  The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition.

Authors:  D Brdiczka; G Beutner; A Rück; M Dolder; T Wallimann
Journal:  Biofactors       Date:  1998       Impact factor: 6.113

View more
  121 in total

1.  Novel therapies in the search for a cure for Huntington's disease.

Authors:  M F Beal; P Hantraye
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

2.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 3.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 4.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

5.  In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice.

Authors:  Gülin Oz; Manda L Vollmers; Christopher D Nelson; Ryan Shanley; Lynn E Eberly; Harry T Orr; H Brent Clark
Journal:  Exp Neurol       Date:  2011-09-22       Impact factor: 5.330

Review 6.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

Review 7.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development.

Authors:  Joanna L Jankowsky; Alena Savonenko; Gabriele Schilling; Jiou Wang; Guilian Xu; David R Borchelt
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 10.  A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules.

Authors:  Motomasa Tanaka; Yoko Machida; Nobuyuki Nukina
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.